Pharmafile Logo

Advent

- PMLiVE

Sanofi and Merck & Co finalise vaccine alliance split

Dissolve Sanofi Pasteur MSD after poor sales growth

- PMLiVE

Sanofi and Boehringer Ingelheim complete €21.8bn asset swap

Exchange of animal health and consumer interests sharpens the firm's focus

Sanofi reception

Sanofi launches insulin combo Soliqua in US

Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy

- PMLiVE

J&J back in frame to buy Actelion after Sanofi talks break down

Parties now in exclusive negotiations about a possible deal

Novartis building

Novartis adds oral eczema drug with Ziarco acquisition

Expands dermatology pipeline with first-in-class, Pfizer-developed treatment prospect

Sanofi reception

Lilly and Boehringer launch first Lantus clone Basaglar in US

Starts biosimilar at 15% discount to Sanofi’s basal insulin product

- PMLiVE

FDA green light for Pfizer’s eczema drug

Blockbuster-hopeful Eucrisa expected to launch early next year at $580 per 60mg tube

Actelion HQ Switzerland

J&J abandons talks with Actelion as another suitor circles

Biotech said to be holding out for a higher offer as speculation of Sanofi interest builds

- PMLiVE

Sanofi launches ‘Highs & Lows’ diabetes awareness campaign

Highlights impact of emotional and psychological factors on effective self-management

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

Amgen’s Repatha unclogs blocked arteries, says study

Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links